Analyst Conference Summary

biotechnology

conference date: November 26, 2024 @ 1:30 PM Pacific Time
for quarter ending: September 30, 2024 (fiscal Q4, fourth quarter 2024)

Forward-looking statements

Overview: Continuing to develop pipeline.

Basic data (GAAP):

Revenue was $ million, sequentially from $0 million, and down from $ million year-earlier. Revenue is from up-front payments and milestones, not sales.

Net income was negative $ million, down sequentially from negative $170 million, and down from negative $ million year-earlier.

Diluted EPS was negative $, down sequentially from negative $1.38, and down from negative $ year-earlier.

Guidance:

none

Conference Highlights:

CEO Christopher Anzalone said ""

All pieces are now in place to transition to a commercial company.

ARO-APOC3 (now plozasiran) for hypertriglyceridemia read out additional Phase 2 data at ACC in fiscal Q2 2024, showing robust improvements. SHTG (severe hypertriglyceridemia) Phase 3 begun in Q2 2024. Planning several new studies. The Phase 3 trial for FCS (familial chylomicronemia syndrome) completed enrollment in Q2 2023. Topline results reported in Q3 2024 included meeting primary endpoint, secondary endpoints, 80% median triglyceride reduction and 94% APOC3 reduction at the higher dose. Full data at European Society of Cardiology on September 2, 2024. Could launch commercially in 2025.

Zodasiran (formerly ARO-ANG3) also read out Phase 2 data at AHA showing reduced levels of triglicerides and LDL cholesterol for mixed dyslipidemia. Hope to launch Phase 3 after regulatory feedback.

In fiscal Q3 2024 Arrowhead completed animal chronic GLP toxicology studies for ARO-RAGE. Goal is to treat inflammatory pulmonary disease. Began Phase 2 asthma study; promising early data. At European Repiratory Congress data demonstrated deep and durable gene silencing for asthma.

See also the Arrowhead Pharmaceuticals pipeline page.

Cash and equivalents (including investments) ended at $ million, down sequentially from $437 million. $ million cash used in operations. In fiscal Q4 signed a $500 million senior secured credit facility with Sixth Street.

Operating expenses of $ million included $ million for R&D and $ million for G&A. Leaving operating income of negative $ million. Other income $ million. Tax benefit $0 million.

Q&A selective summary:

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: